X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4198) 4198
Publication (306) 306
Book Review (102) 102
Newsletter (31) 31
Newspaper Article (16) 16
Book Chapter (14) 14
Magazine Article (9) 9
Conference Proceeding (2) 2
Transcript (2) 2
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (3552) 3552
humans (3368) 3368
index medicus (2584) 2584
infliximab (2096) 2096
female (2033) 2033
male (1849) 1849
tumor necrosis factor-alpha - antagonists & inhibitors (1644) 1644
middle aged (1541) 1541
adult (1540) 1540
etanercept (1421) 1421
treatment outcome (1202) 1202
antibodies, monoclonal - therapeutic use (1103) 1103
rheumatology (1103) 1103
arthritis, rheumatoid - drug therapy (1027) 1027
antibodies, monoclonal - adverse effects (963) 963
antibodies, monoclonal, humanized (933) 933
rheumatoid arthritis (909) 909
antirheumatic agents - therapeutic use (907) 907
therapy (817) 817
antirheumatic agents - adverse effects (809) 809
aged (798) 798
dermatology (747) 747
psoriasis (729) 729
antibodies, monoclonal, humanized - therapeutic use (688) 688
rheumatoid-arthritis (681) 681
efficacy (639) 639
double-blind (626) 626
gastroenterology & hepatology (609) 609
safety (579) 579
methotrexate (575) 575
antibodies, monoclonal, humanized - adverse effects (572) 572
care and treatment (540) 540
crohn disease - drug therapy (540) 540
arthritis (534) 534
drug therapy (527) 527
psoriasis - drug therapy (526) 526
anti-inflammatory agents - therapeutic use (486) 486
immunoglobulin g - therapeutic use (483) 483
receptors, tumor necrosis factor - therapeutic use (479) 479
severity of illness index (475) 475
adalimumab - therapeutic use (464) 464
pharmacology & pharmacy (453) 453
crohn's disease (451) 451
retrospective studies (447) 447
tumor necrosis factor (443) 443
young adult (433) 433
anti-inflammatory agents - adverse effects (431) 431
crohns-disease (431) 431
inflammatory-bowel-disease (408) 408
immunoglobulin g - adverse effects (407) 407
adalimumab - adverse effects (402) 402
tumor necrosis factor-tnf (395) 395
medicine & public health (390) 390
adolescent (387) 387
drug therapy, combination (384) 384
monoclonal antibodies (367) 367
inflammatory bowel disease (341) 341
patients (336) 336
analysis (331) 331
risk factors (327) 327
methotrexate - therapeutic use (299) 299
abridged index medicus (290) 290
rheumatoid factor (287) 287
antibodies, monoclonal - administration & dosage (280) 280
time factors (280) 280
clinical trials (279) 279
disease (278) 278
immunosuppressive agents - therapeutic use (278) 278
ulcerative colitis (276) 276
monoclonal-antibody (272) 272
certolizumab pegol (271) 271
immunology (266) 266
follow-up studies (262) 262
antirheumatic agents - administration & dosage (246) 246
risk (243) 243
remission induction (242) 242
biological products - therapeutic use (240) 240
prospective studies (240) 240
medicine, general & internal (237) 237
trial (237) 237
infliximab - therapeutic use (236) 236
remission (236) 236
placebo-controlled trial (234) 234
double-blind method (232) 232
research (231) 231
arthritis, psoriatic - drug therapy (229) 229
internal medicine (227) 227
necrosis-factor-alpha (227) 227
tumor-necrosis-factor (227) 227
immunosuppressive agents - adverse effects (225) 225
tumor necrosis factor-alpha - immunology (223) 223
biologics (221) 221
dosage and administration (215) 215
child (209) 209
antibodies, monoclonal, humanized - administration & dosage (207) 207
anti-tnf (205) 205
health aspects (203) 203
tnf inhibitors (201) 201
studies (199) 199
inflammatory bowel diseases - drug therapy (197) 197
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4069) 4069
Spanish (48) 48
German (46) 46
French (38) 38
Japanese (25) 25
Italian (12) 12
Portuguese (9) 9
Korean (8) 8
Danish (6) 6
Russian (6) 6
Dutch (5) 5
Hungarian (5) 5
Polish (3) 3
Chinese (2) 2
Czech (2) 2
Arabic (1) 1
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology (United Kingdom), ISSN 1462-0324, 03/2017, Volume 56, Issue 3, pp. 417 - 425
Journal Article
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 5/2017, Volume 51, Issue 5, pp. 388 - 393
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 01/2013, Volume 108, Issue 1, pp. 99 - 105
OBJECTIVES: The risk of non-Hodgkin's lymphoma (NHL) with tumor necrosis factor alpha (TNF-alpha) inhibitors is unclear, whether related to concomitant... 
RHEUMATOID-ARTHRITIS | INFLAMMATORY-BOWEL-DISEASE | THERAPY | AZATHIOPRINE | RISK | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CANCER | MEDLINE | Azathioprine - therapeutic use | Lymphoma, T-Cell - chemically induced | Certolizumab Pegol | United States | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Polyethylene Glycols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Polyethylene Glycols - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Odds Ratio | United States Food and Drug Administration | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | SEER Program | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Adverse Drug Reaction Reporting Systems | Risk Factors | Spondylitis, Ankylosing - drug therapy | Mercaptopurine - adverse effects | Immunoglobulin G - therapeutic use | Immunoglobulin G - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Immunosuppressive Agents - adverse effects | Aged | Adalimumab | Azathioprine - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Cytokine, ISSN 1043-4666, 01/2018, Volume 101, pp. 56 - 63
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in inflammatory diseases such as rheumatoid arthritis and inflammatory... 
Anti-TNF-α therapy | Inflammatory bowel disease | Tumor necrosis factor-α | Rheumatoid arthritis | RHEUMATOID-ARTHRITIS | COLLAGEN-INDUCED ARTHRITIS | CROHNS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | Anti-TNF-alpha therapy | IMMUNOLOGY | FC-FUSION PROTEINS | CERTOLIZUMAB PEGOL | FACTOR RECEPTOR | CELL BIOLOGY | Tumor necrosis factor-alpha | TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | TRANSMEMBRANE TNF | REGULATORY T-CELLS | Adalimumab - genetics | Antirheumatic Agents - administration & dosage | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Inflammatory Bowel Diseases - immunology | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Infliximab - therapeutic use | Polyethylene Glycols - therapeutic use | Antibodies, Monoclonal, Humanized - genetics | Adalimumab - adverse effects | Certolizumab Pegol - adverse effects | Infliximab - adverse effects | Anti-Inflammatory Agents - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Arthritis, Rheumatoid - drug therapy | Tumor Necrosis Factor-alpha - immunology | Anti-Inflammatory Agents - therapeutic use | Antirheumatic Agents - adverse effects | Anti-Inflammatory Agents - administration & dosage | Certolizumab Pegol - therapeutic use | Certolizumab Pegol - genetics | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Disease Models, Animal | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Infliximab - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin Fab Fragments - genetics | Immunoglobulin G - therapeutic use | Immunologic Factors - genetics | Immunoglobulin G - adverse effects | Antibodies, Monoclonal - genetics | Adalimumab - therapeutic use | Animals | Immunoglobulin G - genetics | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Mice | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer
Journal Article
JEADV : Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 2009, Volume 23 Suppl 2, Issue 2, pp. 1 - 70
Journal Article